Takeda gout drug Uloric loses first-line approval after FDA confirms death risks
admin 22nd February 2019 Uncategorised 0Takeda’s gout drug Uloric just got pushed out of the first-line treatment club, thanks to a red flag on safety. After sifting postmarketing data, the FDA decided Uloric is riskier than its rival allopurinol and should be restricted to those who’ve tried the older drug without success.
More: Takeda gout drug Uloric loses first-line approval after FDA confirms death risks
Source: fierce